Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz , and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the ... (more)
http://ift.tt/1kRr4i7
http://ift.tt/1kRr4i7
No comments:
Post a Comment